Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089)

Journal of Thoracic Oncology

Volumn 8, Issue 11, 2013, Pages 1409-1416

  Rittmeyer, Achim ^a   Gorbunova, Vera ^b   Vikström, Anders ^a   Scherpereel, Arnaud ^c   Kim, Joo Hang ^d   Ahn, Myung Ju ^e   Chella, Antonio ^f   Chouaid, Christos ^g   Campbell, Alicyn K ^h   Barlesi, Fabrice ⁱ  

^a Lungenfachklinik Immenhausen ^*  (Sweden)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Yonsei University College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f UNIVERSITY OF PISA   (Italy)

^g HÔPITAL SAINT ANTOINE   (France)

^h GENENTECH INC   (United States)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

Author keywords

AVAPERL; Bevacizumab; Maintenance; Nonsmall cell lung cancer; Patient reported outcomes; Pemetrexed

Indexed keywords

BEVACIZUMAB; CISPLATIN; PEMETREXED;

ARTICLE; CANCER CHEMOTHERAPY; COUGHING; FATIGUE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; LOSS OF APPETITE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84886591723     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182a46bcf     Document Type: Article

References (39)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer, version 2.2012 [Web site]. Available at: gls/f-guidelines.asp. Accessed July 20, 2012
2. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995;71:633-636
3. Lutz S, Norrell R, Bertucio C, et al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: A prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 2001;4:157-165
4. Li WW, Lee TW, Yim AP. Quality of life after lung cancer resection. Thorac Surg Clin 2004;14:353-365
5. Efficace F, Bottomley A, Smit EF, et al; EORTC Lung Cancer Group and Quality of Life Unit. Is a patients self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006;17:1698-1704
6. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742
7. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12:1004-1012
8. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in Collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246
9. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892
10. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:5116-5123
11. Azzoli CG, Temin S, Aliff T, et al; American Society of Clinical Oncology. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011;29:3825-3831
12. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234
14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551
15. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440
16. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-255
17. Behera M, Owonikoko TK, Chen Z, et al. Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. J Clin Oncol 2011;29(Suppl):489s. Abstract 7553
18. Zhang X, Zang J, Xu J, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: A systematic review and meta-analysis. Chest 2011;140:117-126
19. Sandler AB, Byrtek M, Fages S, et al. Clinical patterns and outcomes for the bevacizumab maintenance population in the ECOG 4599 study of patients with advanced non-small cell lung cancer (NSCLC): Results of an exploratory analysis. J Thorac Oncol 2011;6(Suppl 2):s1309. Abstract P3.216
20. Kosty MP, Wozniak AJ, Jahanzeb M, et al. Cumulative exposure to bevacizumab (BV) after induction therapy (tx) correlates with increased survival in patients (pts) with non-small cell lung cancer (NSCLC). Eur J Cancer 2011;47(Suppl 1):619-620. Abstract 9090
21. Kosty MP, Brahmer JR, Jahanzeb M, et al. Use of bevacizumab (BV) after induction therapy is associated with survival benefit in patients (pts) with non-small cell lung cancer (NSCLC) in the ARIES observational cohort study (OCS). Eur J Cancer 2011;47(Suppl 1):598. Abstract 9020
22. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s):544s. Abstract 7526
23. Barlesi F, Scherpereel A, Rittmeyer A, et al. A randomized phase III trial of maintenance bevacizumab with or without pemetrexed following first-line induction with bevacizumab-cisplatin-pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL (MO22089). J Clin Oncol. In press
24. Rittmeyer A, Scherpereel A, Gorbunova VA, et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/ Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013;31(15s):489s.
25. Ahn M, Gervais R, Mezger J, et al. AVAPERL (MO22089)-interim safety of maintenance (mtc) bevacizumab (bev) + pemetrexed (pem) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) after first-line (1L) bev-cisplatin (cis)-pem treatment (tx). Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011. Poster 9112
26. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376
27. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-642
28. European Organization for Research and Treatment of Cancer (EORTC)QLQ-C30 scoring guide, 3rd Ed. 2001 [online]. Available at http://www. eortc.be/home/qol/files/SCManualQLQ-C30.pdf. Accessed July 20, 2012
29. Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2003;123(1 Suppl):97S-104S
30. Cooley ME, Short TH, Moriarty HJ. Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer. Psychooncology 2003;12:694-708
31. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144
32. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 2011;29:2104-2120
33. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: The U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 1996;20:7-9
34. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-679
35. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 1998;317:771-775
36. Cella DF, Patel JD. Improving health-related quality of life in nonsmall- cell lung cancer with current treatment options. Clin Lung Cancer 2008;9:206-212
37. Gridelli C, Bennouna J, de Castro J, et al. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: Treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011;12:407-411
38. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the pointbreak study: A randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-256
39. Galetta D, Pisconti S, Cinieri S, et al. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: A quality of life-oriented randomized phase III study in patients with advanced nonsquamous non-small-cell lung cancer (ERACLE). Clin Lung Cancer 2011;12:402-406